Committee Composition

Robert J. Hugin

Mr. Hugin serves as Celgene’s Executive Chairman. He assumed that role on March 1, 2016. Before serving as Executive Chairman, Mr. Hugin served as Celgene’s Chief Executive Officer, a position he held since June 2010 and Celgene’s Chairman, a position he has held since June 2011. Mr. Hugin served as President and Chief Operating Officer from May 2006 to June 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin joined Celgene in June 1999 as Senior Vice President and Chief Financial Officer. Mr. Hugin is a past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, Danaher Corporation, The Medicines Company and The Darden Foundation, University of Virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.

Chair of the Executive Committee
Recent Stock Transactions by Robert J. Hugin
Date Type Shares Traded Price Range
Oct 26, 2017 Option Execute 62,020 31.21 - 49.48
Jul 28, 2017 Disposition (Non Open Market) 23,073 134.10
Jul 28, 2017 Option Execute 44,500 n/a
Jun 22, 2017 Sell 175,970 134.14
Jun 22, 2017 Option Execute 178,720 24.81 - 36.36
Apr 10, 2017 Option Execute 60,000 29.02
Jan 5, 2017 Option Execute 22,708 27.43
Nov 9, 2016 Automatic Sell 100,000 120.00
Jul 28, 2016 Automatic Sell 100,000 110.00
Jun 20, 2016 Automatic Sell 75,000 100.16
May 17, 2016 Disposition (Non Open Market) 27,000 100.34
Apr 29, 2016 Disposition (Non Open Market) 31,110 103.41
Apr 29, 2016 Option Execute 60,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 1,173 n/a
Feb 12, 2016 Disposition (Non Open Market) 1,173 102.45
Jan 15, 2016 Option Execute 22,680 24.81 - 28.50
Apr 30, 2015 Disposition (Non Open Market) 33,184 108.06
Apr 30, 2015 Option Execute 64,000 n/a
Mar 3, 2015 Acquisition (Non Open Market) 57,723 n/a
Mar 3, 2015 Disposition (Non Open Market) 29,928 118.47 - 118.75
Nov 3, 2014 Disposition (Non Open Market) 433,858 107.41
Nov 3, 2014 Automatic Sell 158,000 106.68
Nov 3, 2014 Option Execute 744,400 7.13 - 17.84
May 2, 2014 Disposition (Non Open Market) 15,555 147.40
May 2, 2014 Option Execute 30,000 n/a
Mar 13, 2014 Disposition (Non Open Market) 39,578 156.00
Mar 13, 2014 Option Execute 95,204 12.59 - 59.01
Feb 12, 2014 Acquisition (Non Open Market) 26,747 n/a
Feb 12, 2014 Disposition (Non Open Market) 13,868 160.54
Jun 16, 2013 Disposition (Non Open Market) 3,370 119.36
Jun 16, 2013 Option Execute 6,500 n/a
May 30, 2013 Automatic Sell 68,087 123.58
May 29, 2013 Disposition (Non Open Market) 242,419 123.09
May 29, 2013 Option Execute 378,592 25.68 - 59.01
Apr 13, 2013 Disposition (Non Open Market) 8,658 123.00
Apr 13, 2013 Option Execute 16,700 n/a
Dec 18, 2012 Disposition (Non Open Market) 12,821 80.03
Dec 18, 2012 Option Execute 20,172 25.68
Apr 14, 2012 Disposition (Non Open Market) 7,725 78.32
Apr 14, 2012 Option Execute 16,667 n/a
Nov 23, 2011 Disposition (Non Open Market) 81,012 60.43
Nov 23, 2011 Option Execute 116,444 25.68 - 59.01
Aug 8, 2011 Buy 10,000 52.70
Jan 17, 2011 Option Execute 36,538 25.68
Mark J. Alles

Mr. Alles serves as Celgene’s Chief Executive Officer. He assumed the role on March 1, 2016. Previously he served as President and Chief Operating Officer. Mr. Alles served as Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, following his promotion to Executive Vice President and Chief Commercial Officer in February 2012. Mr. Alles joined Celgene in April 2004 and served as Vice President, Global Hematology Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his 30-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles is a member of the Celgene Board of Directors, the Trustees for the Healthcare Institute of New Jersey (HINJ), the Board of Gilda’s Club NYC, a not-for-profit organization helping the families of people living with cancer, and a Board Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Recent Stock Transactions by Mark J. Alles
Date Type Shares Traded Price Range
Jul 28, 2017 Disposition (Non Open Market) 1,932 134.10
Jul 28, 2017 Option Execute 4,200 n/a
Feb 14, 2017 Acquisition (Non Open Market) 14,447 n/a
Feb 14, 2017 Disposition (Non Open Market) 6,643 117.02
Dec 2, 2016 Disposition (Non Open Market) 3,018 117.63
Dec 2, 2016 Option Execute 6,560 n/a
Apr 29, 2016 Disposition (Non Open Market) 5,062 103.41
Apr 29, 2016 Option Execute 11,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 25,840 n/a
Feb 12, 2016 Disposition (Non Open Market) 11,889 102.45
Jan 29, 2016 Option Execute 21,938 19.24 - 36.96
Dec 17, 2015 Disposition (Non Open Market) 5,370 112.17
Dec 17, 2015 Option Execute 11,670 n/a
Apr 30, 2015 Disposition (Non Open Market) 5,154 108.06
Apr 30, 2015 Option Execute 11,200 n/a
Mar 1, 2015 Disposition (Non Open Market) 4,078 121.53
Mar 1, 2015 Option Execute 8,334 n/a
Feb 12, 2015 Option Execute 27,505 25.77 - 81.56
Feb 6, 2015 Automatic Sell 117,099 120.68
Feb 6, 2015 Acquisition (Non Open Market) 30,404 n/a
Feb 6, 2015 Disposition (Non Open Market) 13,666 118.75
Feb 6, 2015 Option Execute 107,859 25.77 - 81.56
Feb 12, 2014 Acquisition (Non Open Market) 15,188 n/a
Feb 12, 2014 Disposition (Non Open Market) 6,837 160.54
Dec 27, 2013 Disposition (Non Open Market) 3,501 168.93
Dec 27, 2013 Option Execute 7,777 n/a
Nov 1, 2013 Disposition (Non Open Market) 4,502 151.31
Nov 1, 2013 Option Execute 10,000 n/a
Aug 2, 2013 Sell 5,000 146.47
Aug 2, 2013 Option Execute 15,000 62.35 - 70.63
Jul 31, 2013 Sell 96,406 147.01
Jul 31, 2013 Option Execute 96,406 38.47 - 73.92
Apr 13, 2013 Disposition (Non Open Market) 1,791 123.00
Apr 13, 2013 Option Execute 4,583 n/a
Apr 14, 2012 Disposition (Non Open Market) 902 78.32
Apr 14, 2012 Option Execute 3,056 n/a
Feb 15, 2012 Statement of Ownership 0 n/a
Richard W. Barker, D.Phil. OBE

Richard W. Barker, D.Phil., OBE , has served as one of Celgene's directors and a member of the Audit Committee of Celgene's Board of Directors since January 20, 2012. Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently director of the Centre for Accelerating Medical Innovations, chairman of the Health Innovation Network of South London, UK, a member of the Board of iCO Therapeutics, Inc., a Canadian biotech company, Chairman of Stem Cells for Safer Medicine, a public-private partnership using technology to improve drug safety, and chairman of International Health Partners, a UK charity providing donated medicines to crisis situations. As an experienced healthcare leader and strategist with a distinguished career in the healthcare sector, Dr. Barker brings to his service as a director more than 20 years' experience in the healthcare industry in which he held a range of senior leadership roles in the United States, the United Kingdom and elsewhere internationally. His career has spanned the pharmaceutical, biotechnology and medical informatics sectors, thus giving him a broad perspective on the issues facing both healthcare systems and the pharmaceutical industry.

Recent Stock Transactions by Richard W. Barker, D.Phil. OBE
Date Type Shares Traded Price Range
Jul 1, 2017 Disposition (Non Open Market) 220 129.87
Jul 1, 2017 Option Execute 734 n/a
Sep 23, 2016 Sell 20,000 110.82
Sep 23, 2016 Option Execute 20,000 36.92
Jul 1, 2016 Disposition (Non Open Market) 219 100.70
Jul 1, 2016 Option Execute 733 n/a
Jun 12, 2016 Disposition (Non Open Market) 620 102.91
Jun 12, 2016 Option Execute 2,068 n/a
Jul 1, 2015 Disposition (Non Open Market) 219 118.22
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Disposition (Non Open Market) 620 111.32
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Disposition (Non Open Market) 619 111.32
Jun 12, 2015 Option Execute 2,066 n/a
Jul 25, 2014 Sell 17,600 87.03
Jul 25, 2014 Option Execute 18,600 31.80
Jun 13, 2014 Disposition (Non Open Market) 309 159.99
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Disposition (Non Open Market) 309 160.22
Jun 12, 2014 Option Execute 1,033 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Michael W. Bonney

Michael W. Bonney was elected to the Celgene Board of Directors and Audit Committee on April 14, 2015. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (Cubist) (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until his retirement on December 31, 2014. From January 2002 to June 2003, Mr. Bonney served as Cubist's President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., a biopharmaceutical company, including Vice President, Sales and Marketing from 1999 to 2001. Prior to joining Biogen, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as National Business Director. Since 2014, Mr. Bonney has been a director of Alynylam Pharmaceuticals, Inc., a biopharmaceutical company, where he serves on the audit committee. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, where he serves on the valuation committee and chairs the governance committee and the nominating committee; and chairs the board of trustees of Bates College. Mr. Bonney was a Director of NPS Pharmaceuticals, Inc., a biopharmaceutical company from 2005 until its sale to Shire plc in February 2015, where he was a member of the audit and compensation committees and chaired the governance committee. Mr. Bonney received a B.A. in Economics from Bates College. Mr. Bonney brings to his service as a director his extensive operational, commercial, and senior management experience in the biopharmaceutical industry, as well as his experience serving on the Board of Directors (and certain of their key standing committees) of other companies and trade organizations within the industry.

Michael D. Casey

Michael D. Casey has served as one of our directors since August 2002, and has been our independent Lead Director since June 2007, the  Chairman of the Nominating Committee and a member of the Executive Committee since December 2006, and a member of the Management  Compensation and Development Committee (referred to as the Compensation Committee) since April 2006. Mr. Casey was a member of the  Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman,  President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was  Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products  division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic  Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of  Abaxis Inc. Mr. Casey served as a director of Allos Therapeutics, Inc. through January 2010, AVI BioPharma (now Sarepta Therapeutics, Inc.)  through June 2010 and Durect Corporation through December 2013.  

Mr. Casey brings to his service as a director his significant experience and leadership as President, Chief Executive Officer and senior  officer of several national pharmaceutical companies. In addition to those listed above, he has previously served as a director of several other  pharmaceutical/biotech companies.

Member of the Executive Committee
Recent Stock Transactions by Michael D. Casey
Date Type Shares Traded Price Range
Sep 5, 2017 Acquisition (Non Open Market) 9,250 24.97
Sep 5, 2017 Sell 9,250 139.03
Jul 1, 2017 Option Execute 734 n/a
Jun 21, 2017 Sell 9,250 133.05
Jun 21, 2017 Option Execute 9,250 33.88
Jun 19, 2017 Sell 9,250 125.59
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
May 30, 2017 Option Execute 9,250 28.97
Feb 27, 2017 Sell 7,500 121.55
Feb 27, 2017 Option Execute 7,500 25.58
Jan 12, 2017 Disposition (Non Open Market) 84 n/a
Jan 11, 2017 Disposition (Non Open Market) 84 n/a
Dec 23, 2016 Disposition (Non Open Market) 593 n/a
Oct 18, 2016 Option Execute 7,500 100.06
Aug 22, 2016 Sell 43,134 114.01
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Dec 23, 2015 Sell 20,000 122.11
Dec 21, 2015 Option Execute 60,000 110.84
Sep 8, 2015 Sell 15,000 121.76
Sep 8, 2015 Option Execute 15,000 14.25
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 9, 2015 Sell 1,800 110.50
Jun 9, 2015 Option Execute 1,800 9.93
Jun 8, 2015 Sell 13,200 111.27
Jun 8, 2015 Option Execute 13,200 9.93
Feb 25, 2015 Sell 15,000 123.19
Feb 25, 2015 Option Execute 15,000 8.47
Oct 24, 2014 Sell 15,000 102.94
Oct 24, 2014 Option Execute 15,000 7.09
Aug 14, 2014 Sell 30,000 88.59
Aug 14, 2014 Option Execute 30,000 7.25
Jun 16, 2014 Disposition (Non Open Market) 3,100 n/a
Jun 15, 2014 Option Execute 1,034 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 9, 2014 Disposition (Non Open Market) 15,000 n/a
Jun 9, 2014 Option Execute 15,000 13.68
Mar 4, 2014 Sell 12,770 162.33
Mar 4, 2014 Option Execute 12,770 10.97
Feb 28, 2014 Sell 2,230 164.28
Feb 28, 2014 Option Execute 2,230 10.97
Jun 16, 2013 Option Execute 685 n/a
Jun 15, 2013 Option Execute 1,033 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Apr 30, 2013 Disposition (Non Open Market) 9,294 n/a
Carrie S. Cox

Carrie S. Cox has served as one of our directors since December 2009 and a member of the Audit Committee since March 2010. Ms. Cox currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc., a privately-held regenerative medicine company primarily focused in developing products for vascular disease and for therapeutic filling and soft tissue repair. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical  Business until November 3, 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and has served on their audit and compensation committees, and has been appointed to the Board of Directors of Cardinal Health, Inc. and the Board of Overseers of the University of Pennsylvania Museum of Archaeology and Anthropology. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.

Ms. Cox brings to her service as a director her distinguished career in global healthcare and her significant experience and leadership serving in executive positions of some of the largest and most successful multi-national healthcare companies in the world, including with responsibility for those companies’ financial performance and significant capital and research and development investments.

Recent Stock Transactions by Carrie S. Cox
Date Type Shares Traded Price Range
Jul 1, 2017 Option Execute 734 n/a
Jul 1, 2016 Option Execute 733 n/a
Jun 16, 2016 Option Execute 6,200 n/a
Jul 1, 2015 Option Execute 733 n/a
Jun 16, 2015 Option Execute 2,050 n/a
Oct 25, 2013 Sell 18,750 157.67
Oct 25, 2013 Option Execute 24,900 51.78 - 55.38
Michael A. Friedman, M.D.

Michael A. Friedman , M.D . has served as one of Celgene's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization's Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director's Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens' Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California's stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation and Smith & Nephew plc. He also serves on the Board of Trustees for Tulane University and the California State Stem Cell Initiative. Dr. Friedman brings to his service as a director valuable scientific and operational expertise and leadership skills from his extensive background in cancer research and public health as a senior officer of a leading research institution, deputy and acting commissioner of the FDA, and as an executive officer of a major pharmaceutical company.

Recent Stock Transactions by Michael A. Friedman, M.D.
Date Type Shares Traded Price Range
Jul 1, 2017 Option Execute 734 n/a
Jun 22, 2017 Automatic Sell 5,000 135.00
Jun 22, 2017 Option Execute 5,000 59.06
Jun 21, 2017 Automatic Sell 5,000 130.00
Jun 21, 2017 Option Execute 5,000 59.06
Jun 19, 2017 Automatic Sell 5,000 125.00
Jun 19, 2017 Option Execute 5,000 59.06
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Nov 9, 2016 Automatic Sell 18,600 116.10
Nov 9, 2016 Option Execute 18,600 31.80
Oct 3, 2016 Automatic Sell 56,116 103.66
Oct 3, 2016 Option Execute 56,116 29.00 - 29.96
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Julia A. Haller, M.D

Dr. Julia Haller was elected to the Board of Directors in October 2015.  Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia.  She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and Co-Director of the Wills Vision Research Center at Jefferson.

In 1986, Dr. Haller served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the faculty.  In 2007, Dr. Haller assumed leadership of the Wills Eye Hospital.  Dr. Haller has received numerous academic and professional honors and has published over 300 scientific articles and book chapters.  Dr. Haller received an A.B. from Princeton University and her M.D. from Harvard Medical School.  She is a member of numerous scientific advisory boards and data and safety monitoring committees and is also a past member of the Boards of Trustees of Princeton University. 

Gilla Kaplan Ph.D.

Gilla Kaplan , Ph.D . has served as one of Celgene's directors since April 1998 and is a member of the Nominating Committee and, until April 2015, was a member of the Audit Committee. Dr. Kaplan was appointed Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation in January 2014. She previously served as Senior Advisor to the Global Health Program, Tuberculosis and member of the International Scientific Advisory Committee for the Global Health Program of the Bill and Melinda Gates Foundation. Dr. Kaplan was head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the New Jersey Medical School, Newark, New Jersey, where she was appointed full Member in 2002 and Assistant Director in 2006. Dr. Kaplan also was previously appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Prior to that, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor. Dr. Kaplan brings to her service as a director valuable scientific expertise and leadership skills from her distinguished career in medical research, including her current role as Director of the Global Health Program, Tuberculosis at the Bill and Melinda Gates Foundation and her past roles and experiences in the field of immunology.

Recent Stock Transactions by Gilla Kaplan Ph.D.
Date Type Shares Traded Price Range
Sep 12, 2017 Sell 9,250 141.56
Sep 12, 2017 Option Execute 9,250 33.88
Aug 2, 2017 Sell 7,500 134.52
Jul 1, 2017 Option Execute 734 n/a
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Jun 1, 2017 Option Execute 9,250 28.97
Mar 30, 2017 Sell 14,033 123.83
Mar 3, 2017 Option Execute 7,500 25.58
Sep 19, 2016 Option Execute 7,500 29.26
Sep 15, 2016 Sell 9,710 106.44
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 15, 2016 Option Execute 6,200 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Apr 4, 2016 Automatic Sell 15,967 101.84
Dec 21, 2015 Automatic Sell 14,464 110.62
Dec 21, 2015 Option Execute 14,464 16.21
Sep 10, 2015 Sell 15,000 122.45
Sep 10, 2015 Option Execute 15,000 14.25
Jul 1, 2015 Option Execute 733 n/a
Jun 16, 2015 Option Execute 4,110 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 10, 2015 Sell 15,000 111.74
Jun 10, 2015 Option Execute 15,000 9.93
Feb 26, 2015 Sell 15,000 122.89
Feb 26, 2015 Option Execute 15,000 8.47
Jan 2, 2015 Automatic Sell 45,536 113.47
Jan 2, 2015 Option Execute 45,536 16.21
Dec 8, 2014 Automatic Sell 15,000 118.20
Dec 8, 2014 Option Execute 15,000 7.09
Sep 8, 2014 Automatic Sell 30,000 93.73
Sep 8, 2014 Option Execute 30,000 7.25
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 9, 2014 Automatic Sell 15,000 161.62
Jun 9, 2014 Option Execute 15,000 13.68
Feb 13, 2014 Option Execute 15,000 10.97
Dec 9, 2013 Automatic Sell 15,000 172.17
Dec 9, 2013 Option Execute 15,000 11.21
Sep 4, 2013 Automatic Sell 15,000 143.92
Sep 4, 2013 Option Execute 15,000 11.23
Jun 13, 2013 Option Execute 1,033 n/a
Dec 11, 2012 Automatic Sell 32,400 81.42
Dec 11, 2012 Option Execute 48,000 8.41
Jun 17, 2012 Option Execute 685 n/a
Mar 28, 2012 Sell 8,000 78.45
Mar 28, 2012 Option Execute 8,000 8.41
Jun 17, 2011 Option Execute 685 n/a
James J. Loughlin

James J. Loughlin has served as one of our directors since January 2007, as Chairman of the Audit Committee since June 2008 and a member of the Compensation Committee since June 2008. Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors and the Audit Committee of Edge Therapeutics, Inc., a privately-held biopharmaceutical company, and InspireMD, a publicly-traded medical device manufacturer.

Mr. Loughlin brings to his service as a director his valuable experiences as National Director of the Pharmaceuticals Practice at KPMG, his service as Chairman of the Pension and Investment Committee of the KPMG Board and his service on various other committees and foundations. In particular, through his professional association with KPMG, including a five-year term as member of the Board of Directors of KPMG, Mr. Loughlin brings to our Board of Directors an extensive background in accounting and financial reporting, qualifying him as an audit committee financial expert (as that term is defined in the regulations of the SEC).

Recent Stock Transactions by James J. Loughlin
Date Type Shares Traded Price Range
Jul 1, 2017 Option Execute 734 n/a
Jun 26, 2017 Automatic Sell 18,500 133.57
Jun 26, 2017 Option Execute 18,500 24.97 - 33.88
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
May 1, 2017 Sell 9,250 124.00
May 1, 2017 Option Execute 9,250 28.96
Aug 23, 2016 Sell 27,500 114.10
Aug 23, 2016 Option Execute 27,500 25.58 - 26.65
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Feb 22, 2016 Sell 2,100 104.12
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Aug 22, 2014 Sell 20,000 91.25
Aug 22, 2014 Option Execute 20,000 28.65
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 16, 2013 Option Execute 685 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Jun 22, 2012 Buy 600 60.29
Jun 17, 2012 Option Execute 685 n/a
Jun 16, 2012 Option Execute 685 n/a
Jun 17, 2011 Option Execute 685 n/a
Jun 16, 2011 Option Execute 685 n/a
Ernest Mario, Ph.D.

Ernest Mario, Ph.D . has served as one of Celgene's directors since August 2007 and is a member of the Nominating Committee since August 2007, the Executive Committee since June 2008 and Chairman of the Compensation Committee since August 2014. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario also serves as a director of publicly-traded healthcare companies: Capnia, Inc. (chairman of the board), Boston Scientific Corporation (member of audit committee and chair of compensation committee), Chimerix Inc. (chairman of the board and member of the nominating and governance committee), Kindred Biosciences Inc. (chairman of the audit committee and member of the compensation committee), XenoPort Inc. (member of the nominating and governance committee) and Tonix Pharmaceuticals Holding Corp. (member of the compensation committee). He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy's highest honor. Dr. Mario brings to his service as a director his significant executive leadership experience, including his experience leading several pharmaceutical companies, as well as his membership on public company boards and foundations. He also has extensive experience in financial and operations management, risk oversight, and quality and business strategy.

Member of the Executive Committee
Recent Stock Transactions by Ernest Mario, Ph.D.
Date Type Shares Traded Price Range
Oct 30, 2017 Option Execute 13,600 31.80
Aug 10, 2017 Sell 18,506 130.52
Jul 1, 2017 Option Execute 734 n/a
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Feb 27, 2017 Sell 12,000 121.24
Feb 1, 2017 Disposition (Non Open Market) 3,570 n/a
Sep 23, 2016 Sell 15,000 109.42
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 16, 2016 Option Execute 2,055 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Apr 26, 2016 Option Execute 5,000 31.80
Feb 1, 2016 Option Execute 18,600 29.00
Dec 28, 2015 Sell 40,000 119.36
Jul 31, 2015 Sell 19,442 131.73
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Feb 3, 2015 Option Execute 7,666 27.69
Oct 27, 2014 Sell 100,000 102.85
Jul 24, 2014 Option Execute 5,000 27.69
Jun 15, 2014 Option Execute 3,100 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Apr 7, 2014 Option Execute 6,000 55.38
Mar 25, 2014 Disposition (Non Open Market) 196 n/a
Mar 25, 2014 Disposition (Non Open Market) 196 n/a
Mar 3, 2014 Disposition (Non Open Market) 2,210 n/a
Mar 3, 2014 Disposition (Non Open Market) 2,210 n/a
Feb 18, 2014 Disposition (Non Open Market) 1,020 n/a
Feb 18, 2014 Disposition (Non Open Market) 1,020 n/a
Feb 5, 2014 Sell 13,500 151.87
Feb 5, 2014 Option Execute 13,500 59.89 - 67.75
Feb 4, 2014 Option Execute 7,000 60.02
Jan 7, 2014 Option Execute 2,000 59.89
Oct 24, 2013 Option Execute 6,000 59.89
Aug 14, 2013 Option Execute 4,625 54.35
Jun 13, 2013 Option Execute 1,033 n/a
Jun 5, 2013 Option Execute 15,000 59.89
May 29, 2013 Buy 1,000 123.72 - 123.73
Jun 17, 2012 Option Execute 685 n/a
Apr 27, 2012 Option Execute 16,958 44.94 - 49.93
Dec 5, 2011 Buy 2,000 61.30 - 61.40
Nov 2, 2011 Acquisition (Non Open Market) 2,000 63.00
Aug 1, 2011 Buy 5,000 58.10
Jun 17, 2011 Option Execute 685 n/a
Mar 15, 2011 Buy 2,500 53.33
Jan 31, 2011 Buy 10,000 51.58

Stock transaction information provided by EDGAR Online. Celgene Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

  Audit Compensation Executive Nominating, Governance and Compliance
Robert J. Hugin
X Image of Robert J. Hugin
Robert J. Hugin
Executive Chairman

Mr. Hugin serves as Celgene’s Executive Chairman. He assumed that role on March 1, 2016. Before serving as Executive Chairman, Mr. Hugin served as Celgene’s Chief Executive Officer, a position he held since June 2010 and Celgene’s Chairman, a position he has held since June 2011. Mr. Hugin served as President and Chief Operating Officer from May 2006 to June 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin joined Celgene in June 1999 as Senior Vice President and Chief Financial Officer. Mr. Hugin is a past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, Danaher Corporation, The Medicines Company and The Darden Foundation, University of Virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.

    Committee Chair for Executive Committee  
Richard W. Barker, D.Phil. OBE
Independent
X Image of Richard W. Barker, D.Phil. OBE
Richard W. Barker, D.Phil. OBE
Former Director General of the Association of British Pharmaceutical Industry (ABPI)

Richard W. Barker, D.Phil., OBE , has served as one of Celgene's directors and a member of the Audit Committee of Celgene's Board of Directors since January 20, 2012. Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently director of the Centre for Accelerating Medical Innovations, chairman of the Health Innovation Network of South London, UK, a member of the Board of iCO Therapeutics, Inc., a Canadian biotech company, Chairman of Stem Cells for Safer Medicine, a public-private partnership using technology to improve drug safety, and chairman of International Health Partners, a UK charity providing donated medicines to crisis situations. As an experienced healthcare leader and strategist with a distinguished career in the healthcare sector, Dr. Barker brings to his service as a director more than 20 years' experience in the healthcare industry in which he held a range of senior leadership roles in the United States, the United Kingdom and elsewhere internationally. His career has spanned the pharmaceutical, biotechnology and medical informatics sectors, thus giving him a broad perspective on the issues facing both healthcare systems and the pharmaceutical industry.

Member of Audit Committee      
Michael W. Bonney
Independent
X Image of Michael W. Bonney
Michael W. Bonney
Former Chief Executive Officer of Cubist Pharmaceuticals Inc.

Michael W. Bonney was elected to the Celgene Board of Directors and Audit Committee on April 14, 2015. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (Cubist) (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until his retirement on December 31, 2014. From January 2002 to June 2003, Mr. Bonney served as Cubist's President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., a biopharmaceutical company, including Vice President, Sales and Marketing from 1999 to 2001. Prior to joining Biogen, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as National Business Director. Since 2014, Mr. Bonney has been a director of Alynylam Pharmaceuticals, Inc., a biopharmaceutical company, where he serves on the audit committee. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, where he serves on the valuation committee and chairs the governance committee and the nominating committee; and chairs the board of trustees of Bates College. Mr. Bonney was a Director of NPS Pharmaceuticals, Inc., a biopharmaceutical company from 2005 until its sale to Shire plc in February 2015, where he was a member of the audit and compensation committees and chaired the governance committee. Mr. Bonney received a B.A. in Economics from Bates College. Mr. Bonney brings to his service as a director his extensive operational, commercial, and senior management experience in the biopharmaceutical industry, as well as his experience serving on the Board of Directors (and certain of their key standing committees) of other companies and trade organizations within the industry.

Member of Audit Committee      
Michael D. Casey
Independent
X Image of Michael D. Casey
Michael D. Casey
Former President and Chief Executive Officer of Matrix Pharmaceutical, Inc.

Michael D. Casey has served as one of our directors since August 2002, and has been our independent Lead Director since June 2007, the  Chairman of the Nominating Committee and a member of the Executive Committee since December 2006, and a member of the Management  Compensation and Development Committee (referred to as the Compensation Committee) since April 2006. Mr. Casey was a member of the  Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman,  President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was  Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products  division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic  Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of  Abaxis Inc. Mr. Casey served as a director of Allos Therapeutics, Inc. through January 2010, AVI BioPharma (now Sarepta Therapeutics, Inc.)  through June 2010 and Durect Corporation through December 2013.  

Mr. Casey brings to his service as a director his significant experience and leadership as President, Chief Executive Officer and senior  officer of several national pharmaceutical companies. In addition to those listed above, he has previously served as a director of several other  pharmaceutical/biotech companies.

  Member of Compensation Committee Member of Executive Committee Committee Chair for Nominating, Governance and Compliance Committee
Carrie S. Cox
Independent
X Image of Carrie S. Cox
Carrie S. Cox
Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc.

Carrie S. Cox has served as one of our directors since December 2009 and a member of the Audit Committee since March 2010. Ms. Cox currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc., a privately-held regenerative medicine company primarily focused in developing products for vascular disease and for therapeutic filling and soft tissue repair. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical  Business until November 3, 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and has served on their audit and compensation committees, and has been appointed to the Board of Directors of Cardinal Health, Inc. and the Board of Overseers of the University of Pennsylvania Museum of Archaeology and Anthropology. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.

Ms. Cox brings to her service as a director her distinguished career in global healthcare and her significant experience and leadership serving in executive positions of some of the largest and most successful multi-national healthcare companies in the world, including with responsibility for those companies’ financial performance and significant capital and research and development investments.

Member of Audit Committee      
Michael A. Friedman, M.D.
Independent
X Image of Michael A. Friedman, M.D.
Michael A. Friedman, M.D.
Emeritus Chief Executive Officer, City of Hope

Michael A. Friedman , M.D . has served as one of Celgene's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization's Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director's Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens' Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California's stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation and Smith & Nephew plc. He also serves on the Board of Trustees for Tulane University and the California State Stem Cell Initiative. Dr. Friedman brings to his service as a director valuable scientific and operational expertise and leadership skills from his extensive background in cancer research and public health as a senior officer of a leading research institution, deputy and acting commissioner of the FDA, and as an executive officer of a major pharmaceutical company.

      Member of Nominating, Governance and Compliance Committee
Julia A. Haller, M.D
Independent
X Image of Julia A. Haller, M.D
Julia A. Haller, M.D
Ophthalmologist-in-Chief of the Wills Eye Hospital

Dr. Julia Haller was elected to the Board of Directors in October 2015.  Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia.  She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and Co-Director of the Wills Vision Research Center at Jefferson.

In 1986, Dr. Haller served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the faculty.  In 2007, Dr. Haller assumed leadership of the Wills Eye Hospital.  Dr. Haller has received numerous academic and professional honors and has published over 300 scientific articles and book chapters.  Dr. Haller received an A.B. from Princeton University and her M.D. from Harvard Medical School.  She is a member of numerous scientific advisory boards and data and safety monitoring committees and is also a past member of the Boards of Trustees of Princeton University. 

Member of Audit Committee      
Gilla Kaplan Ph.D.
Independent
X Image of Gilla Kaplan Ph.D.
Gilla Kaplan Ph.D.
Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation

Gilla Kaplan , Ph.D . has served as one of Celgene's directors since April 1998 and is a member of the Nominating Committee and, until April 2015, was a member of the Audit Committee. Dr. Kaplan was appointed Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation in January 2014. She previously served as Senior Advisor to the Global Health Program, Tuberculosis and member of the International Scientific Advisory Committee for the Global Health Program of the Bill and Melinda Gates Foundation. Dr. Kaplan was head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the New Jersey Medical School, Newark, New Jersey, where she was appointed full Member in 2002 and Assistant Director in 2006. Dr. Kaplan also was previously appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Prior to that, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor. Dr. Kaplan brings to her service as a director valuable scientific expertise and leadership skills from her distinguished career in medical research, including her current role as Director of the Global Health Program, Tuberculosis at the Bill and Melinda Gates Foundation and her past roles and experiences in the field of immunology.

      Member of Nominating, Governance and Compliance Committee
James J. Loughlin
Independent
X Image of James J. Loughlin
James J. Loughlin
Retired Partner KPMG, LLP

James J. Loughlin has served as one of our directors since January 2007, as Chairman of the Audit Committee since June 2008 and a member of the Compensation Committee since June 2008. Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors and the Audit Committee of Edge Therapeutics, Inc., a privately-held biopharmaceutical company, and InspireMD, a publicly-traded medical device manufacturer.

Mr. Loughlin brings to his service as a director his valuable experiences as National Director of the Pharmaceuticals Practice at KPMG, his service as Chairman of the Pension and Investment Committee of the KPMG Board and his service on various other committees and foundations. In particular, through his professional association with KPMG, including a five-year term as member of the Board of Directors of KPMG, Mr. Loughlin brings to our Board of Directors an extensive background in accounting and financial reporting, qualifying him as an audit committee financial expert (as that term is defined in the regulations of the SEC).

Committee Chair for Audit Committee Member of Compensation Committee    
Ernest Mario, Ph.D.
Independent
X Image of Ernest Mario, Ph.D.
Ernest Mario, Ph.D.
Former Deputy Chairman and Chief Executive of Glaxo Holdings plc.

Ernest Mario, Ph.D . has served as one of Celgene's directors since August 2007 and is a member of the Nominating Committee since August 2007, the Executive Committee since June 2008 and Chairman of the Compensation Committee since August 2014. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario also serves as a director of publicly-traded healthcare companies: Capnia, Inc. (chairman of the board), Boston Scientific Corporation (member of audit committee and chair of compensation committee), Chimerix Inc. (chairman of the board and member of the nominating and governance committee), Kindred Biosciences Inc. (chairman of the audit committee and member of the compensation committee), XenoPort Inc. (member of the nominating and governance committee) and Tonix Pharmaceuticals Holding Corp. (member of the compensation committee). He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy's highest honor. Dr. Mario brings to his service as a director his significant executive leadership experience, including his experience leading several pharmaceutical companies, as well as his membership on public company boards and foundations. He also has extensive experience in financial and operations management, risk oversight, and quality and business strategy.

  Committee Chair for Compensation Committee Member of Executive Committee Member of Nominating, Governance and Compliance Committee
Committee Chair = Chair Committee Member = Member

Stock transaction information provided by EDGAR Online. Celgene Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.